Latest filing published 01 Mar 2022 for Sangamo Therapeutics, INC.
Insider track record
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
No signal scores available.
Robert J. Schott: trading record in brief
Robert J. Schott (senior executive) discloses dealings in Sangamo Therapeutics, Inc to SEC (Form 4). In total, 3 filings cover trades dated from 12 February 2021 to 25 February 2022.
No open-market purchase or sale appears among the filings, only grants, plan transactions and other operations. Because grants and exercises are largely decided by remuneration plans, they are not counted as purchases here.
Most recently, on 1 March 2022, the filings show a share grant in Sangamo Therapeutics, Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 4 days. The legal deadline for a Form 4 is two business days after the transaction. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Companies and markets linked to Robert J. Schott
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 41,000 shares0Common StockSEC:0001209191-22-014176:0
- 5,463 shares@ US$5.76100.0% of flowCommon StockSEC:0001209191-22-012765:0
2 of 2 declarations
